<DOC>
	<DOCNO>NCT02068443</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 24-week treatment metformin hydrochloride 500 mg daily add alogliptin ( SYR-322 ) 25 mg type 2 diabetic patient inadequate glycemic control despite treatment alogliptin 25 mg addition diet exercise therapy .</brief_summary>
	<brief_title>Comparative Study Evaluate Efficacy Safety When Metformin Hydrochloride 500 mg Once Daily Added SYR-322 25 mg Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg Addition Diet Exercise Therapy</brief_title>
	<detailed_description>The drug test study call alogliptin metformin hydrochloride . Alogliptin combination metformin hydrochloride test treat people Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control despite treatment alogliptin addition diet exercise . This study look efficacy safety alogliptin 25 mg daily ( QD ) + metformin hydrochloride 500 mg QD compare alogliptin 25 mg QD + metformin hydrochloride 250 mg twice daily ( BID ) alogliptin 25 mg QD administer alone . The study enrol 374 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Alogliptin 25 mg QD + metformin hydrochloride 500 mg QD - Alogliptin 25 mg QD + metformin hydrochloride 250 mg BID - Alogliptin 25 mg QD This multi-center trial conduct Japan . The overall time participate study 36 week ( 12-week screening period 24-week treatment period ) . Participants make multiple visit clinic include final visit 24 week start study medication .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Has diagnosis type 2 diabetes mellitus . 2 . Has hemoglobin A1c ( HbA1c ) ( National glycohemoglobin standardization program [ NGSP ] ) ≥6.9 % &lt; 10.5 % 8 week start screen period ( Week 4 ) . 3 . Has HbA1c ( NGSP ) difference 4 week start screen period ( Week 8 ) 8 week start screen period ( Week 4 ) within 10.0 % ( round first decimal place ) value 4 week start screen period ( Week 8 ) . 4 . Has certain diet therapy exercise therapy ( ) screen period . 5 . Has receive alogliptin stable dose regimen ( breakfast , 25 mg/day ) screening period . 6 . In opinion investigator subinvestigator , participant consider appropriate receive biguanide addon alogliptin , end screen period ( Week 0 ) . 7 . In opinion investigator subinvestigator , participant unlikely require change dose antihypertensive agent ( include discontinuation suspension ) additional antihypertensive agent study . 8 . Is male female age ≥20 year &lt; 75 year . Participants age ≥65 year &lt; 75 year need consider eligible enrollment investigator subinvestigator end screening period ( Week 0 ) take consideration cardiovascular disorder pulmonary function disorder , renal function , hepatic function , etc . 9 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study . 10 . Is treated outpatient setting screen period . 11 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 12 . Signs date write , informed consent form prior initiation study procedure . 1 . Has receive antidiabetic drug alogliptin ( include insulin preparation glucagonlike peptidase1 [ GLP1 ] analog preparation ) screen period . 2 . Has clinical manifestation hepatic impairment . 3 . Has alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≥ 2.5 × upper limit normal screening period . 4 . Has clinical manifestation renal impairment , include mild impairment . 5 . Has history lactic acidosis . 6 . Has cardiovascular disease include shock , heart failure , myocardial infarction pulmonary embolism , serious pulmonary function disorder , condition predispose him/her hypoxemia . 7 . Has dehydration gastrointestinal dysfunction diarrhea vomiting , may cause dehydrated state . 8 . Has malnutrition , starve state , hyposthenia , pituitary gland dysfunction adrenal insufficiency . 9 . Has serious cardiac disease , serious cerebrovascular disorder , serious pancreatic hematological disease ( eg , participant require inpatient treatment hospitalize treatment within 24 week prior start screen period ) . 10 . In opinion investigator subinvestigator , participant clinically significant abnormal hematological parameter hemoglobin , hematocrit , erythrocytes screen period . 11 . Has systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 110 mmHg screen period . 12 . Has condition require insulin blood glucose control ( eg , severe ketosis , diabetic coma precoma , type 1 diabetes , severe infection , pre postoperative condition , serious trauma ) . 13 . Has malignancy . 14 . Has history hypersensitivity allergy dipeptidylpeptidase4 ( DPP4 ) inhibitor biguanides . 15 . Is habitual drinker consume 100 mL alcohol average daily . 16 . Has history drug abuse ( define illicit drug use ) history alcohol dependence . 17 . Requires exclude medication prohibit matter study . 18 . Has receive combination therapy alogliptin benzoate metformin hydrochloride previous clinical study therapeutic agent . 19 . Has receive investigational compound within 12 week prior start screen period ( Week 12 ) . 20 . Is participant another clinical study time sign informed consent . 21 . If female , participant pregnant lactating ; intend become pregnant time signing inform consent end study ; intend donate ova period . 22 . Is study site employee , immediate family member , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) , may consent duress . 23 . Is consider ineligible study reason investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>